FluGen Revenue and Competitors

Madison, WI USA

Location

$71.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • FluGen's estimated annual revenue is currently $2.3M per year.(i)
  • FluGen's estimated revenue per employee is $178,846
  • FluGen's total funding is $71.4M.

Employee Data

  • FluGen has 13 Employees.(i)
  • FluGen grew their employee count by -7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.8M1820%N/AN/A
#2
$1.9M1233%N/AN/A
#3
$1.4M9-31%N/AN/A
#4
$4.2M278%N/AN/A
#5
$5.2M670%$45.5MN/A
#6
$1.7M1157%N/AN/A
#7
$1.4M980%N/AN/A
#8
$0.9M6-33%N/AN/A
#9
$16.3M10521%N/AN/A
#10
$0.9M620%N/AN/A
Add Company

With eight employees, FluGen was founded in 2007 and received initial support from angel investors and other sources including WARF. Based in the University Research Park in Madison, its first product to enter clinical trials will be the vaccine delivery patch. The market for influenza products alone was estimated at more than $6 billion for 2010.

keywords:N/A

$71.4M

Total Funding

13

Number of Employees

$2.3M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

FluGen News

2022-04-06 - Shock to the System: FluGen Develops Novel Flu Vaccine Technology

... single-replication, intranasal flu vaccine based on an invention by UW Madison virologists and FluGen co-founders Yoshihiro Kawaoka,...

2021-08-02 - FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus

MADISON, Wis., Aug. 2, 2021 /PRNewswire/ -- FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of results from its Phase 2 human challenge study of Bris2007 M2SR, the Company's investigational, supra- ...

2021-05-25 - FluGen Initiates NIH-Funded Trial of M2SR Flu Vaccine; First Study in Adults Up to Age 85

MADISON, Wis., May 25, 2021 /PRNewswire/ -- FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the initiation of the first study in older adults of M2SR, the company's investigational supra-seasonal, live, single-rep ...

2015-08-25 - FluGen Completes $12M Series A Financing

FluGen Inc., a Madison, WI-based biotechnology company developing a novel “universal” influenza vaccine, completed a $12m Series A financing. Backers included Venture Investors LLC, the Wisconsin Alumni Research Foundation (WARF), the State of Wisconsin Investment Board, and other new and exist ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M1386%N/A
#2
$1.1M13-7%N/A
#3
$2M1318%N/A
#4
$2M13-13%N/A
#5
N/A140%N/A